The present invention involves the preparation of vascular endothelial growth actor (VEGF) variants which provide materials that are selective in respect to binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.

 
Web www.patentalert.com

< Enzyme-mediated modification of fibrin for tissue engineering: incorporation of proteins

< Adenoviral vectors encoding an antibody fused to a CD4 extracellular domain

> Dimerizing agents, their production and use

> Human CTLA-4 antibodies

~ 00242